Neurology Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II), By Study Design (Interventional), By Indication, By Region, And Segment Forecasts, 2022 - 2030
Neurology Clinical Trials Market Growth & Trends
The global neurology clinical trials market size is expected to reach USD 8,052.9 million by 2030, registering a CAGR of 5.6% from 2023 to 2030, according to a new report by Grand View Research, Inc. This is largely attributed to big pharma companies conducting innovative trials in neurology, increased government funding from the National Institute of Neurological Disorders and Stroke (NINDS), and the high prevalence of neurological disorders worldwide.
Neuroscience continues to receive a healthy investment. For instance, in November 2022, NRG Therapeutics raised Series A funding of USD 18.3 million for the development of mitochondrial therapeutics to treat neurodegenerative ailments such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease. The adoption of similar initiatives in the future is expected to support market growth.
A significant number of people worldwide suffer from neurological disorders. For instance, as per the statistics from Parkinson's Foundation, every year 60,000 Americans are diagnosed with PD and more than 10 million people are living with the disease around the world. In terms of Epilepsy, the WHO states that more than 65 million people worldwide are affected by it. The disease is most prevalent in low- and middle-income countries, which account for 80.0% of epilepsy cases. A high prevalence of neurological disorders is expected to boost demand for clinical trials and thus support the market.
Neurology is considered as one of the major areas where clinical trials are conducted. As per the Pharma R&D Annual Review, in 2021, Neurology trials were the third area where clinical trials were majorly focused. The Pharma R&D Annual Review stated that for neurology above 2,900 drugs were under trial and in the year 2022 the number of drugs for clinical studies in the area of neurology accounted for more than 3,200 active drugs. An increasing number of drugs entering clinical trials in the area of neurology are expected to support the market in the post-pandemic period.
Neurology Clinical Trials Market Report Highlights
- The phase II segment dominated the market and accounted for a maximum revenue share of 46.3% in 2022. A majority number of neurology clinical trials are currently in Phase 2, this is supporting the segment market
- The interventional segment held the largest market revenue share of 96.1% in 2022. A high number of neurology clinical trials conducted through this study design type is promoting the growth of the segment market
- The Huntington's disease segment is anticipated to register the fastest CAGR of 6.0% during the forecast period. This is largely due to the fact that there is a high demand for the medicines used for Huntington's disease worldwide as there are no medications available for treating this disease
- North America dominated the market and accounted for a revenue share of 47.0% in 2022. The rising prevalence of neurological disorders and the presence of a large number of players in clinical trials drive the market in the region. These are some of the key reasons for the high market share
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Phase
- 1.1.2. Study Design
- 1.1.3. Indication
- 1.1.4. Indication by Study Design
- 1.1.5. Indication by Phase
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR’s internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
- 1.6.1.1. Approach 1: Commodity flow approach
- 1.6.2. Volume price analysis (Model 2)
- 1.6.2.1. Approach 2: Volume price analysis
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
- 1.9.1. Objective 1
- 1.9.2. Objective 2
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- Chapter 3. Neurology Clinical Trials Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & growth prospect mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.1.1. Increasing prevalence of neurological diseases such as Alzheimer disease, epilepsy, and stroke
- 3.3.1.2. Growing adoption of novel technologies in clinical research
- 3.3.1.3. Significant number of CROs providing neurology clinical research services
- 3.3.1.4. Increasing funding for neurological studies by public organizations
- 3.3.2. Market restraint analysis
- 3.3.2.1. High cost associated with neurology clinical studies.
- 3.3.2.2. High failure rate coupled with patient dropout issues associated with neurological clinical trials.
- 3.4. Neurology Clinical Trials Market Analysis Tools
- 3.4.1. Porter’s Five Forces Analysis
- 3.4.2. PEST Analysis
- 3.5. COVID-19 Impact and Reformation Strategy
- Chapter 4. Neurology Clinical Trials Market: Phase Estimates & Trend Analysis
- 4.1. Definitions and Scope
- 4.2. Neurology Clinical Trials Market: Phase Market Share Analysis, 2022 & 2030
- 4.2.1. Phase I
- 4.2.2. Phase II
- 4.2.3. Phase III
- 4.2.4. Phase IV
- Chapter 5. Neurology Clinical Trials Market: Study Design Estimates & Trend Analysis
- 5.1. Definitions and Scope
- 5.2. Neurology Clinical Trials Market: Study Design Market Share Analysis, 2022 & 2030
- 5.2.1. Interventional
- 5.2.2. Observational
- 5.2.3. Expanded Access
- Chapter 6. Neurology Clinical Trials Market: Indication Estimates & Trend Analysis
- 6.1. Definitions and Scope
- 6.2. Neurology Clinical Trials Market: Indication Market Share Analysis, 2022 & 2030
- 6.2.1. Epilepsy
- 6.2.2. Parkinson's Disease (PD)
- 6.2.3. Huntington's Disease
- 6.2.4. Stroke
- 6.2.5. Traumatic Brain Injury (TBI)
- 6.2.6. Amyotrophic Lateral Sclerosis (ALS)
- 6.2.7. Muscle regeneration
- 6.2.8. Others
- Chapter 7. Neurology Clinical Trials Market: Indication By Study Design Estimates & Trend Analysis
- 7.1. Definitions and Scope
- 7.2. Neurology Clinical Trials Market: Indication By Study Design Market Share Analysis, 2022 & 2030
- 7.2.1. Epilepsy
- 7.2.1.1. Interventional
- 7.2.1.2. Observational
- 7.2.1.3. Expanded Access
- 7.2.2. Parkinson's Disease (PD)
- 7.2.2.1. Interventional
- 7.2.2.2. Observational
- 7.2.2.3. Expanded Access
- 7.2.3. Huntington's Disease
- 7.2.3.1. Interventional
- 7.2.3.2. Observational
- 7.2.3.3. Expanded Access
- 7.2.4. Stroke
- 7.2.4.1. Interventional
- 7.2.4.2. Observational
- 7.2.4.3. Expanded Access
- 7.2.5. Traumatic Brain Injury (TBI)
- 7.2.5.1. Interventional
- 7.2.5.2. Observational
- 7.2.5.3. Expanded Access
- 7.2.6. Amyotrophic Lateral Sclerosis (ALS)
- 7.2.6.1. Interventional
- 7.2.6.2. Observational
- 7.2.6.3. Expanded Access
- 7.2.7. Muscle regeneration
- 7.2.7.1. Interventional
- 7.2.7.2. Observational
- 7.2.7.3. Expanded Access
- 7.2.8. Others
- 7.2.8.1. Interventional
- 7.2.8.2. Observational
- 7.2.8.3. Expanded Access
- Chapter 8. Neurology Clinical Trials Market: Indication By Phase Estimates & Trend Analysis
- 8.1. Definitions and Scope
- 8.2. Neurology Clinical Trials Market: Indication By Phase Market Share Analysis, 2022 & 2030
- 8.2.1. Epilepsy
- 8.2.1.1. Phase I
- 8.2.1.2. Phase II
- 8.2.1.3. Phase III
- 8.2.1.4. Phase IV
- 8.2.2. Parkinson's Disease (PD)
- 8.2.2.1. Phase I
- 8.2.2.2. Phase II
- 8.2.2.3. Phase III
- 8.2.2.4. Phase IV
- 8.2.3. Huntington's Disease
- 8.2.3.1. Phase I
- 8.2.3.2. Phase II
- 8.2.3.3. Phase III
- 8.2.3.4. Phase IV
- 8.2.4. Stroke
- 8.2.4.1. Phase I
- 8.2.4.2. Phase II
- 8.2.4.3. Phase III
- 8.2.4.4. Phase IV
- 8.2.5. Traumatic Brain Injury (TBI)
- 8.2.5.1. Phase I
- 8.2.5.2. Phase II
- 8.2.5.3. Phase III
- 8.2.5.4. Phase IV
- 8.2.6. Amyotrophic Lateral Sclerosis (ALS)
- 8.2.6.1. Phase I
- 8.2.6.2. Phase II
- 8.2.6.3. Phase III
- 8.2.6.4. Phase IV
- 8.2.7. Muscle regeneration
- 8.2.7.1. Phase I
- 8.2.7.2. Phase II
- 8.2.7.3. Phase III
- 8.2.7.4. Phase IV
- 8.2.8. Others
- 8.2.8.1. Phase I
- 8.2.8.2. Phase II
- 8.2.8.3. Phase III
- 8.2.8.4. Phase IV
- Chapter 9. Neurology Clinical Trials Market: Regional Estimates & Trend Analysis
- 9.1. Regional market share analysis, 2022 & 2030
- 9.2. North America
- 9.2.1. U.S.
- 9.2.1.1. U.S. market estimates and forecast, 2018-2030
- 9.2.2. Canada
- 9.2.2.1. Canada market estimates and forecast, 2018-2030
- 9.3. Europe
- 9.3.1. U.K.
- 9.3.1.1. U.K. market estimates and forecast, 2018-2030
- 9.3.2. Germany
- 9.3.2.1. Germany market estimates and forecast, 2018-2030
- 9.3.3. France
- 9.3.3.1. France market estimates and forecast, 2018-2030
- 9.3.4. Italy
- 9.3.4.1. Italy market estimates and forecast, 2018-2030
- 9.3.5. Spain
- 9.3.5.1. Spain market estimates and forecast, 2018-2030
- 9.4. Asia Pacific
- 9.4.1. Japan
- 9.4.1.1. Japan market estimates and forecast, 2018-2030
- 9.4.2. China
- 9.4.2.1. China market estimates and forecast, 2018-2030
- 9.4.3. India
- 9.4.3.1. India market estimates and forecast, 2018-2030
- 9.4.4. Australia
- 9.4.4.1. Australia market estimates and forecast, 2018-2030
- 9.4.5. South Korea
- 9.4.5.1. South Korea market estimates and forecast, 2018-2030
- 9.5. Latin America
- 9.5.1. Brazil
- 9.5.1.1. Brazil market estimates and forecast, 2018-2030
- 9.5.2. Mexico
- 9.5.2.1. Mexico market estimates and forecast, 2018-2030
- 9.5.3. Argentina
- 9.5.3.1. Argentina market estimates and forecast, 2018-2030
- 9.5.4. Colombia
- 9.5.4.1. Colombia market estimates and forecast, 2018-2030
- 9.6. MEA
- 9.6.1. South Africa
- 9.6.1.1. South Africa market estimates and forecast, 2018-2030
- 9.6.2. Saudi Arabia
- 9.6.2.1. Saudi Arabia market estimates and forecast, 2018-2030
- 9.6.3. UAE
- 9.6.3.1. UAE market estimates and forecast, 2018-2030
- Chapter 10. Competitive Landscape
- 10.1. Market Share Analysis
- 10.2. Participant Categorization
- 10.3. Recent Development and Impact Analysis
- Chapter 11. Company Profiles
- 11.1. Company Overview
- 11.2. Financial Performance
- 11.3. Strategic Initiatives
- 11.3.1. Expansions
- 11.3.2. Partnerships and Collaborations
- 11.3.3. Acquisitions
- 11.3.3.1. Novartis
- 11.3.3.2. Covance
- 11.3.3.3. Med pace
- 11.3.3.4. Charles River Laboratories
- 11.3.3.5. Syneous Health
- 11.3.3.6. Icon Plc
- 11.3.3.7. GlaxoSmithKline
- 11.3.3.8. Aurora healthcare
- 11.3.3.9. Biogen
- 11.3.3.10. IQVIA
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook